Krystal Biotech Q2 net loss widens to $33.2 million as VYJUVEK launch begins
Krystal Biotech reported a second-quarter 2023 net loss of $33.2 million, or $(1.25) per share, up from $28.1 million, or $(1.10) per share, a year earlier. The filing reports no revenue figure; it cites 121 Patient Start Forms for VYJUVEK in the first six weeks after its May 19 FDA approval, and $505.9 million in cash, cash equivalents and investments at June 30, 2023.
Key points
- Q2 2023 net loss was $33.2 million, or $(1.25) per share, versus $28.1 million, or $(1.10) per share, in Q2 2022.
- General and administrative expenses rose to $25.9 million from $17.9 million, and R&D expenses rose to $12.1 million from $10.9 million.
- As of June 30, the company had received 121 VYJUVEK Patient Start Forms, 30 of them for dominant dystrophic epidermolysis bullosa.
- Cash, cash equivalents and investments totaled $505.9 million on June 30, 2023.
The filing
Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2023.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.